METHOD OF MODULATING THE IMMUNE RESPONSE SYSTEM IN MAMMALS

Abstract: A method of modulating the immune response system in a warm-blooded animal by the administration of N-­ substituted--phenylthioanilines, N-substituted-phenyl­ sulfinylanilines, and N-substituted-phenylsulfonylanilines, certain of which are new compounds.

Description: This invention is concerned with a novel method of modulating the immune response system in a warm -blooded animal which comprises administering to said animal an effective amount of a compound of the formula: EMI1.1 wherein R1 is hydrogen, nitro or chloro; R2 is hydrogen or chloro; R3 is hydrogen, fluoro, chloro, bromo, nitro, alkoxy having up to 3 carbon atoms, acetylamino, B-hydroxyethylamino or -NHCOCH2NHCH3; R4 is hydrogen or chloro; R5 is hydrogen or chloro; R6 is hydrogen or alkyl having up to 3 carbon atoms; R7 is hydrogen, alkyl having up to 3 carbon atoms, - CH2CN2, -COCH2NH2, -COCH2NHCH3, -COCH2C1, -COCH2CH2C1, EMI1.2 wherein R is alkyl having up to 4 carbon atoms such as methyl, isopropropyl, n -butyl, tert-butyl, etc.; and Z is thio (-S-), sulfinyl (-SO-) or sulfonyl (SO2-); with the proviso that the phenyl ring bearing the R1, R2, R3 and R4 substituents is mono-substituted except for polychloro substitution; together with the pharmacologically acceptable acidaddition salts thereof; in association with a pharmaceuti -cally acceptable carrier. In addition, this invention is concerned with novel compounds of the formula: EMI2.1 wherein R8 is hydrogen, fluoro, chloro, or bromo and R9 is hydrogen or chloro with the proviso that one of R8 and Rg must be hydrogen but R8 and Rg may not both be hydrogen; and R10 is selected from the group consisting of -COCH2NH2, EMI2.2 and -CH2CN together with their pharmaceutically acceptable salts. Certain of the active compounds of this invention may be prepared in accordance with the following reaction scheme: EMI3.1 wherein R8, Rg, R10 and Z are as hereinabove defined. In accordance with the above reaction scheme, a 4-amino -substituted phenyl sulfide, sulfoxide or sulfone (1) is reacted with R10-X where R10 is -COCH2CH2C1, -COCH2C1, -CH2CN or -COR and X is chloro or bromo in a solvent such as toluene at reflux for several hours. The solvent is evaporated and the product crystallized from a solvent such as ethanol giving (2). The compounds (2), where R10 is -COCH2C1, may then be reacted with methylamine or ammonia to give the products (3) where Rlo is -COCH2NH2 or -COCH2NHCH3. The compounds (2) where R10 is -COCH2C1 may also be treated with sodium azide to give azido derivatives which are then reduced with hydrogen sulfide and triethylamine or hydrogen and Raney Nickel to give the products (3) where R10 is -COCH2Nh2. The compounds (2) where Rlo is -CH2Cn may be reacted with sodium azide to give the products (3) where R10 is EMI4.1 A bis(z-aminophenyl)sulfide, sulfoxide or sulfone (4) where Z is -S-, -SO- or -S02- is reacted with chloroacetyl chloride to give a bisl-(chloroacetamido)phenyllsulfide, sulfoxide or sulfone (5) which is then reacted with methylamine in ethanol at reflux for several hours giving (6) where Z is as described above. Most of the active compounds of the present invention may be readily prepared in accordance with the following reaction scheme wherein R1, R2, R3, R4, R5, R6 and R7 are as hereinbefore defined. EMI5.1 In accordance with the above reaction scheme, an appropriately substitued thiophenol (7) is condensed with a substituted schloro-nitrobenzene (8) in an approximately 50% aqueous-lower alkanol solvent at the reflux temperature (750-1000C.) thereof for about 4-20 hours in the presence of an acid acceptor such as pellet KOH in soda ash. Dilution of the reaction mixture with water precipitates the corresponding substituted nitrodiphenyl sulfide product (9) which may be recrystallized from organic solvents such as ethanol, dimethylformamide, methylene chloride, etc. Oxidation of the sulfide (9) to the corresponding sulfone (10) is accomplished by treatment with 30% aqueous hydrogen peroxide in glacial acetic acid as solvent at about 1000C. for a few hours. Hydrogenation of the sulfone (10) is achieved in an inert solvent such as tetrahydrofuran or dioxane with Raney nickel catalyst at ambient temperatures for a few hours or until the stoichiometric amount of hydrogen is absorbed. Filtration of the reaction mixture followed by concentration of the filtrate provides the product (11) wherein R6 and R7 are both hydrogen. Hydrogenation of the sulfone (10) as just described but also in the presence of a carbonyl compound such as 37% formaldyhyde, acetaldyhyde, propionalydehyde or acetone provides the product (11) wherein R6 and R7 are lower alkyl. Hydrogenation of the sulfide (9) as described hereinabove for the sulfone (10) provides the sulfide (12) wherein R6 and R7 are each hydrogen or lower alkyl. Oxidation of the sulfide (12) to the corresponding sulfoxide (13) is accomplished by treatment with 30% aqueous hydrogen peroxide in glacial acetic acid as solvent at about 500C. for a few hours. The use of immunomodulants and chemotherapeutic adjuvants constitutes a new therapeutic approach to the treatment of immune deficiencies and cancer and is based on the concept that there are distinctive antigens in or on most tumor cells (embryonal or transplantation antigens) that distinguish them from normal host cells. A majority of tumor immunologists favor the view that potentially malignant cells constantly arise but because of their "foreigness" they are normally eliminated by a competent humoral and cellular immune system. Occasionally however, tumor cells escape this immune surveillance and continue to reproduce cancer results. The reason for the failure of the normally efficient immune surveillance mechanisms are not fully understood but it is thought that the immune system becomes less effective with increasing age. It is depressed in certain genetic immuno-deficiency diseases, in various bacterial, fungal or viral infections, and in patients undergoing immunosuppressive therapy. The growth of the neoplasm itself, as well as the various therapeutic modalities designed to treat the disease, e.g., cytotoxic chemotherapy and radiation, leads to a still greater depression of host resistance and results in an increased susceptability to both exogenous and endogenous infections and perhaps accounts for the re-initiation of tumor growth and metastasis which frequently follows treatment-induced tumor remission. If depression of the immune system can result in the growth of malignancies, regulation of any facet of the immune response may help the host to eliminate residual cancer cells. Therefore, it is desirable to search for chemical agents (i.e., immunoregulants) capable of restoring and stimulating host immune defense mechanisms in order to overcome the deficiencies which account for susceptability to disease and failure to eradicate the cancer. Such immuno-regulating agents would likely be incapable of arresting the growth of a large tumor but their clinical utility would derive from their capacity to enhance normal immune surveillance mechanisms in patients whose tumor burden has been reduced by surgical, radiotherapeutic or chemotherapeutic methods. Experimental studies in animal have demonstrated the antitumor potential of a number of immuno-regulants including live organisms of bacillus Calmett-Guerin (BCG), heat-killed cells of Corynebacterium parvum, polynucleotides, and the anthelmintic drug, levamisole. These substances has been shown to stimulate cellular immunity and to produce tumor regression. Some successes have been claimed in early clinical trials with BCG against malignant melanoma and acute leukemia, and with levamisole against lung cancer and breast cancer. Although the antitumor effects produced by these agents have been promising, significant therapeutic benefits have yet to be realized. Since this is a new therapeutic approach, new drug and methods of treatments must receive careful clinical evaluation in order to reveal their full potential. Modern research is directed to the discovery of a drug similar to, but more potent than, known immunoregulants such as levamisole that would be effective in the eradication of tumor cells when used in conjunction with standard therapeutic measures. Stimulators of host resistance may be detected in animal models that can, in fact, detect both immunostimulators and anticancer agents. Mice are put in a condition simulating immunodepression. common to cancer patients. This is accomplished by infecting mice with a leukemia virus which produces both leukemia and a disease-related immunodepression. Effective drugs are recognized by their ability to restore or enhance the antibody response in the experimental mice, or to inhibit tumor progression. The active compounds and novel compositions of the present invention are active as immunomodulators when tested according to the following procedure, Restoration of Antibody Formation in Mice with Rauscher Virus-Induced Leukemia. Infection of Baltic mice with Rauscher leukemia virus (RLV) is characterized by: 1) a rapidly developing viremia, 2) suppression of the primary antibody response to antigens administered a few days after virus infection, 3) a progressive enlargement of the spleen (spenomegaly), and 4) death resulting from splenic rupture and hemorrhage. The protocol used to infect Baltic mice with RLV and to test drugs for anticancer and/or immunostimulating activity is as follows: Day 0: Inject 0.2 ml of a 20% (w/v) RLV -infected spleen cell extract intra peritoneally (IP) into groups of 5 Baltic mice. The spleen cell extract is prepared from mice infected with RLV 21 days previously. Day +6,+7,+8: Test compounds are administrered orally or by IP injection, in 0.5 ml. of normal saline containing 0.2% Noble agar. Day 7: Inject 0.5 ml. of IP of a thrice saline washed 10% suspension of sheep red blood cells (S-RBC). Day 14: Bleed mice from the retro-orbital sinus; pool blood from each group. Serum, harvested from pooled blood of each group of mice is stored at 4 C. for 24 hours. Hemagglutinin tests are performed by standard procedures using a microtier technique. Acceptable hemagglutinin titer for leukemic (immunosuppressed) mice is = 1:128. The positive control compounds are Poly I:C (polyinosinic acid:polycy tidylic acid) and Sarcosine administered intraperitoneally on days +6, +7, and +8. Acceptable positive control hemagglutinin titers are 4-fold higher than the titers obtained in leukemic control mice. Typical compounds of this invention are active in this test, in that they produce a 4-fold or higher increase in hemagglutinin titer to sheep-RBC's, relative to the placebo treated, RLV-infected control mice. Results of this test appear in Table I below. TABLE I Antibody Restoration in Mice with Rauscher Virus-Induced Leukemia EMI10.1 <SEP> Fol <SEP> increase <SEP> in <SEP> Serum <tb> <SEP> Compound <SEP> Dose(mg/kg) <SEP> Rout <SEP> Hemagglutinin <SEP> Titer <tb> 3-chloro-4'-(p-nitrophenylthio)- <SEP> 1800 <SEP> Oral <SEP> 64 <tb> propionanilide <tb> 2-methylamino-4'-(p-nitrophenylthio)- <SEP> 200 <SEP> Oral <SEP> 8 <tb> acetanilide, <SEP> hydrochloride <tb> 2-chloro-4'-(m-chlorophenylsulfonyl)- <SEP> 1800 <SEP> Oral <SEP> 8 <tb> acetanilide <tb> 2-amino-4'-(m-chlorophenylsulfonyl)- <SEP> 400 <SEP> Oral <SEP> 16 <tb> acetanilide <tb> 4'-(m-chlorophenylsulfonyl)-2- <SEP> 800 <SEP> Oral <SEP> 4 <tb> -methylamino-acetanilide <tb> TABLE I (continued) EMI11.1 <SEP> Fold <SEP> increase <tb> <SEP> Compound <SEP> Dose(mg/kg) <SEP> Route <SEP> in <SEP> Serum <tb> <SEP> Hemagglutinin <tb> <SEP> Titer <tb> bis-[f-(2-methylaminoacetamido)- <SEP> 1800 <SEP> Oral <SEP> 8 <tb> <SEP> -phenyl]sulfone <tb> 4'-(p-chlorophenylsulfonyl)- <SEP> 100 <SEP> Oral <SEP> 16 <tb> <SEP> -acetanilide <tb> 2-amino-4'-(p-chlorophenylsulfonyl)- <SEP> 100 <SEP> Oral <SEP> 4 <tb> -acetanilide <SEP> hydrochloride <tb> [p-(p-chloropenylsulfonyl)anilino]- <SEP> 400 <SEP> Oral <SEP> 16 <tb> -acetonitrile <tb> 5-[[p-(p-chlorophenylsulfonyl)- <SEP> 400 <SEP> Oral <SEP> 8 <tb> -anilino]methyl]-1H-tetrazole <tb> 4-fluoro-4'-(2-aminoacetamido)- <SEP> 300 <SEP> Oral <SEP> 16 <tb> -diphenylsulfone <tb> TABLE I (continued) EMI12.1 <SEP> Fold <SEP> increase <SEP> in <tb> <SEP> Compound <SEP> Dose(mg/kg) <SEP> Route <SEP> Serum <SEP> hemagglutinin <tb> <SEP> Titer <tb> N-[4-(4-fluorophenylsulfonyl)- <SEP> 400 <SEP> Oral <SEP> 64 <tb> -phenyl]acetamide <tb> N-[4-(4-bromophenylsulfonyl)- <SEP> 200 <SEP> Oral <SEP> 16 <tb> -phenyl]acetamide <tb> N-[4-(3-chlorophenylsulfonyl)- <SEP> 100 <SEP> Oral <SEP> 4 <tb> -phenyl]acetamide <tb> TABLE I (continued) EMI13.1 <SEP> Fold <SEP> increase <SEP> in <tb> <SEP> Serum <SEP> Hemagglutinin <tb> <SEP> Compound <SEP> Dose(mg/kg) <SEP> Route <SEP> Titer <tb> N-[4-[(4-fluorophenyl)sulfinyl]- <SEP> 100 <SEP> IP <SEP> 4 <tb> phenyl]acetamide <tb> N-[4-[(4-methoxyphenyl)thio]phenyl]- <SEP> 400 <SEP> Oral <SEP> 4 <tb> acetamide <tb> N-[4-[(4-methoxyphenyl)-sulfinyl]- <SEP> 400 <SEP> Oral <SEP> 4 <tb> phenyl]acetamide <tb> N-[4-[(4-chlorophenyl)sulfinyl]- <SEP> 100 <SEP> IP <SEP> 4 <tb> phenyl]acetamide <tb> N-[4-[(4-chlorophenyl)thio]phenyl]- <SEP> 100 <SEP> IP <SEP> 16 <tb> acetamide <tb> N-[(4-[(4-bromophenyl)thio]phenyl]- <SEP> 100 <SEP> IP <SEP> 8 <tb> acetamide <SEP> 200 <SEP> Oral <SEP> 16 <tb> N-4-[(4-bromophenylsulfinyl]phenyl]- <SEP> 400 <SEP> Oral <SEP> 8 <tb> acetamide <tb> N-[4-[(4-fluorophenyl)sulfonyl]phe- <SEP> 400 <SEP> Oral <SEP> 16 <tb> nyl]-2-methylpropanamide <tb> TABLE I (continued) EMI14.1 <SEP> Compound <SEP> Dose <SEP> Fold <SEP> Increase <SEP> in <SEP> Serum <tb> <SEP> (mg/kg) <SEP> Route <SEP> Hemagglutinin <SEP> Titer <tb> p-(p-fluorophenylsulfonyl)aniline <SEP> 100 <SEP> IP <SEP> 8 <tb> p-(o-nitrophenylthio)aniline <SEP> 400 <SEP> Oral <SEP> 4 <tb> p-(2,4,5-trichlorophenylsulfonyl)aniline <SEP> 400 <SEP> Oral <SEP> 4 <tb> p-(p-bromophenylsulfonyl)aniline <SEP> 100 <SEP> IP <SEP> 8 <tb> o-(phenylthio)aniline <SEP> 400 <SEP> Oral <SEP> 4 <tb> p-(2,4,5-trichlorophenylthio)aniline <SEP> 400 <SEP> Oral <SEP> 4 <tb> p-(2,5-dichlorophenylthio)aniline <SEP> 400 <SEP> Oral <SEP> 16 <tb> p-(m-chlorophenylsulfonyl)aniline <SEP> 400 <SEP> Oral <SEP> 8 <tb> p-(3,4-dichlorophenylthio)aniline <SEP> 25 <SEP> Oral <SEP> 8 <tb> TABLE I (continued) EMI15.1 <SEP> Dose <SEP> Fold <SEP> Increase <SEP> in <SEP> Serum <tb> <SEP> Compound <SEP> (mg/kg) <SEP> Route <SEP> Hemagglutinin <SEP> Titer <tb> p-(p-methoxyphenylsulfonyl)aniline <SEP> 400 <SEP> Oral <SEP> 16 <tb> p-(3,4-dichlorophenylsulfonyl)aniline <SEP> 100 <SEP> IP <SEP> 8 <tb> 3-chloro-4-(p-chlorophenylsulfonyl)aniline <SEP> 400 <SEP> Oral <SEP> 4 <tb> p-(p-chlorophenylsulfonyl)aniline <SEP> 50 <SEP> IP <SEP> 16 <tb> 2-[[p-(p-aminophenylsulfonyl)phenyl]amino]ethanol <SEP> 800 <SEP> Oral <SEP> 4 <tb> 4-acetylamino-4'-aminodiphenylsulfone <SEP> 100 <SEP> IP <SEP> 4 <tb> p-[(p-fluorophenyl)sulfinyl]-N,N-dimethylben- <SEP> 100 <SEP> IP <SEP> 4 <tb> zeneamine <tb> Poly <SEP> I:C <SEP> 10 <SEP> IP <SEP> 16 <tb> The compounds of the present invention are effective as immunomodulators (that is, they modulate the immune response) when administered orally in amounts ranging from about 5 mg. to about 400 mg. per kilogram of body weight per day. A preferred dosage regimen for optimum results would be from about 5 mg. to about 50 mg. per kilogram of body weight per day, and such dosage units are employed that a total of from about 350 mg. to about 3.5 grams of the active compound for a subject of about 70 kg. of body weight are administered in a 24 hour period. This dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A practical advantage of this invention is that the active compound may be administered-in any convenient manner as the oral or buccal routes. The compounds of the present invention may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard of soft shell gelatin capsules, or they may be compressed into tablets. For orally therapeutic administration, the active compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.5% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of active ingredient in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 50 and 250 mg. of active compound. The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potatoe starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. A syrup or elixir may contain the active compound, sucrose as a sweeetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as a cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. The invention will be described in greater detail in conjunction with the following specific examples. Example 1 2-Chloro-4'-(E-nitrophenylthio)acetanilide A mixture of 10.0 g or 4-amino-4'-nitrophenylsulfide and 4.5 g of chloroacetyl chloride in 150 ml of toluene was refluxed for 48 hours. The solvent was removed by evaporation and the residue crystallized from ethanol, giving 12 g of the desired product, mp 217-2190C. Example 2 3-Chloro-4'4E-nitrophenylthio)propionanalide To a mixture of 5.0 g of 4-amino-4'-nitrodiphenylsulfide in 120 ml of toluene and 20 ml of dichloromethane was added 2.6 g of 3-chloropropionyl chloride in 15 ml of toluene, dropwise. The mixture was heated and stirred at reflux for 2 hours then the solvent was evaporated and the residue recrystallized from ethanol, giving 6.2 g of the desired product, mp 145-1470C. Example 3 2-Methylamino-41 - (±-nitrophenylthio) acetanilide hydrochloride A mixture of 3.0 g of 2-chloro-4'-(2-nitro- phenylthio) acetanilide and a 4.0% aqueous solution of methylamine in ethanol was refluxed for 4 hours. The solvent was evaporated, the residue dissolved in dichloromethane and crystallized by the addition of hexane, giving 2.25 g of the desired product, mp 86-890C. Example 4 2-Chloro-4'-(m-chlorophenylsulfonyl)acetanilide To a stirred mixture of 28.8 g of 3-chlorothiophenol and 23.3 g of sodium carbonate in 250 ml of water was added 31.5 9 of 4-chloro nitrobenzene followed by 200 ml of ethanol. The mixture was stirred at reflux for 4 hours and then filtered. The solid was treated with dichloromethane and water and then recrystallized from toluene, giving 42.1 g of 3-chlorophenyl-4'-nitrophenylsulfide. A mixture of 40.0 g of 3-chlorophenyl-4'-nitrophenylsulfide, 0.7 ml of 30% hydrogen peroxide and 230 ml of glacial acetic acid was hydrogenated in a Parr apparatus for 1.5 hours. The reaction mixture was filtered and the solid washed with two 150 ml portions of dioxane. Evaporation of the filtrate and wash gave a residue which was crystallized from ethanol, giving 43.4 g of 3-chloro phenyl-4 '-nitrophenylsulfone. A 12.5 g portion of 3-chlorophenyl-4'-nitrophenylsulfone in dioxane was hydrogenated in a Parr apparatus with Raney nickel catalyst, giving 4.9 g of 3-chloro phenyl-4' -aminophenylsulfone. To a solution of 2.57 g of 3-chlorophenyl4'-aminophenylsulfone and 3.0 ml of 2-methoxyethylether in 0.5 ml of dioxane was added 0.5 ml of chloroacetylchloride. The mixture was heated at 90-1100C. for one hour. The solvent was evaporated and the residue recrystallized from cold hexane, than ethanol, giving 1.3 g of the desired product, mp 130-1320C. Example 5 2-Amino-4 '- (m-chlorophenylsulfonyl) acetanilide A mixture of 2.0 g of 2-chloro-4'-(m-chloro- phenylsulfonyl) acetanilide, 0.41 g of soduim azide, 20 ml of water and 40 ml of ethanol was refluxed for 3.5 hours and then evaporated to dryness. The residue was crystallized from ethanol, giving 1.2 g of 2-azido-4' (m-chlorophenylsulfonyl) acetanilide, mp 125-1260C. A mixture of 12 g of 2-azido-4'-(m-chlorophenyl- sulfonyl) acetanilide and 8 ml of Raney nickel in 150 ml of p-dioxane and 50 ml of ethanol was hydrogenated in a Parr shaker with an initial pressure of 30 psi of hydrogen for 2 hours. The mixture was filtered through a celite pad and the volatiles removed from the filtrate. The residue was crystallized from ±-dioxane, giving 6.2 g of the desired product, mp 195-1960C. Example 6 4 '-(m-Chlorophenylsulfonyl)-2-methylaminoacetanilide A mixture of 6.0 g of 2-chlorophenyl-4'-(mchloro-phenylsulfonyl)acetanilide, 1100 ml of methylamine and 20 ml of ethanol was refluxed for 3.5 hours. The solvent was evaporated and the residue partitioned between dichloromethane and water. The dichloromethane portion giving 2.48 g of the desired product, mp 110-1120C. Example 7 3is--1p-(2-methylaminoacetamido)phenyllsulfone To a stirred solution of 24.83 g of bis-(p -amino-phenylsulfone in 100 ml of dioxane and 200 ml of dimethoxyethyl ether at 500C. was added a 1:1 mixture of chloro-acetylchloride and dimethoxyethyl ether. The mixture was heated at 900C for 3.5 hours and then allowed to stand at ambient temperature. The solid was collected and crystallized giving 10.2 of bis-[(p-(chloroacetamino) -phenyl]sulfone. A mixture of 5.0 g of bis-[(p-(chloroacetamido)phenyl] sulfone and 100 ml of methylamine in 100 ml of ethanol was refluxed for 3 hours. The solvent was evaporated and the residue recrystallized from ethanol, giving 2.8 g of the desired product, mp 166-1680C. Example 8 4'-(p-Chlorophenylsulfonyl)acetanilide A mixture of 70.1 g of N-acetylsulfanilyl chloride and 60 g of aluminum chloride in 200 ml of E-chlorobenzede was heated until the evolution of hydrogen chloride ceased and then refluxed for 2 hours. The chlorobenzene was removed by decantation and the residue diluted with ether. The resulting gummy solid was recovered by filtration and treated with dilute hydrochloric acid and ethanol. The resulting solid was collected, dissolved in hot ethanol and concentrated, giving 19.31 g of the desired product as pale gray crystals, mp 187.5-1880C. Example 9 2-Amino-4'-(p-chlorophenylsulfonyl)-acetanilide hydrochloride A mixture of 5.14 g of 4'-)p-chlorophenyl -sulfonylacetanilide, 1.42 g of chloroacetyl chloride, 26 ml of dioxane and 14 ml of methoxyethyl ether was heated with stirring at 90-1000C. for 2 1/2 hours, then worked up, giving 7.9 g of 2-chloro-4'[p-(p-chlorophenylsulfonyl) phenyl ] acetanil ide. A mixture of 6.0 g of the above compound and 120 ml of liquid ammonia was heated at 140 C. in a sealed bomb for several hours, then opened and allowed to stand overnight. The mixture was treated with acetone, filtered, evaporated and crystallized from hexane with refridgeration. Further recrystallization gave 1.8 g of the desired product after conversion to the hydrochloride salt, mp 143-1450C. Example 10 [p-(p-Chlorophenylsulfonyl)anilino]acetonítrile A mixture of 43.5 g of p-chlorothiophenol, 47.1 g of ±-chloronitrobenzene, 39.0 g of sodium carbonate, 120 ml of water and 150 ml of ethanol was heated at 1000C. for 19 hours, giving 80.0 g of 4-chloro-4'-nitrodiphenylsulfide, which was then dissolved in a mixture of 400 ml of acetic acid and 100 ml of 30% hydrogen peroxide and stirred at 1000C. for one hour, giving 80.2 g of the corresponding sulfonyl derivative. The sulfonyl derivative was catalytically hydrogenated to the corresponding amino derivative. A 16.1 g portion of the amino derivative, 4.98 g of bromoacetanonitrile, 9.0 g of sodium bicarbonated and 18 ml of l-methyl-2-pyrrolidinone was mixed, stirred at 106 0C. under nitrogen for 3 hours and then quenched with ice water giving 11.8 g of the desired product as tan crystals, mp 130-1320C. Example 11 5-[[2-(p-Chlorophenylsulfonyl)anilino]methyl]-lH-tetrazole A reaction mixture comprising 6.14 g of lp-(p- -chlorophenylsulfonyl)anilino]acetonitrile, 1.43 g of sodium azide, 30 mg of lithium chloride, 1.18 g of ammonium chloride and 10 ml of dimethylformamide was stirred ar 90C for 34 hours them filtered. The solvent was removed in vacuo, the residue suspended in 50 ml of water and acified with hydrochloric acid to ph 2. The resulting solid was collected and recrystallized from acetic acid,giving 5.4 g of the desired product as tan crystals, mp 102-105qC. Example 12 4-Fluoro-4t aminoacetamido)diphenylsulfone 4-Amino-4'-fluorodiphenylsulfone was prepared from p-chloronitrobenzene and p-chloronitrobenzene by converting the sulfide to the sulfone and reducing the nitro substituent to the amino derivative by the procedures giving in Example 10. A 15.0 g portion of the sulfone was then stirred in 200 ml of dichloromethane in an ice bath and 9.18 ml of triethylamine were added. A solution of 5.26 ml of chloroacetyl chloride were added. dichloromethane was added at such a rate as to maintain the temperature below 250C. The ice bath was removed, the mixture stirred for one hour at room temperature then washed twice with water, treated with charcoal, dried and concentrated to a solid, giving 13.7 g of 4-fluoro-4' - (chloroacetamido)diphenylsulfone. An 11.0 g portion of this solid was combined with 2.4 g of sodium azide in 50 ml of dimethylsulfoxide, stirred overnight, poured into 500 ml of ice and water and the solid collected. This solid was recrystallized from 150 ml of toluene, giving 9.8 g of 2-azido -N-(4-(4-fluorophenylsulfonyl]phenyl]acetamide. A 2.0 g portion of this azide was dissolved in 40 ml of dioxane and subjected to hydrogenation with with Raney nickel catalyst for 1.5 hours. The mixture was filtered, the filtrate concentrated to a residue and recrystallized from ethanol giving 944 mg of the desired product as white crystals, mp 181-184 0C. Example 13 N-[4-(4-Fluorophenylsulfonyl)-phenyl]acetamide A 2.51 g portion of 4-amino-4'-fluorodiphenyl sulfone was slurried in 100 ml of dichloromethane. A 1.84 ml portion of triethylamine was added and the mixture was cooled in an ice bath. A 1.05 ml portion of acetyl chloride in 60 ml of dichloromethane was added dropwise over 15 minutes, the ice bath was removed and the mixture stirred at room temperature for 48 hours. The solution was washed successively with water, sodium bicarbonate solution, water and sodium chloride solution then dried and concentrated to a solid. The solid was recrystallized from 125 ml of toluene, giving 1.6 g of the desired product as white cystals, mp 181-183 0C. Example 14 N-14-(4-Bromophenylsulfonyl)phenyllacetamide - A mixture of 28.35 g of 4-bromothiophenol, 23.55 g of 4-chloronitrobenzene, 19 g of sodium carbonate, 100 ml of ethanol and 75 ml of water was heated at 1000C for 4 hours, then diluted with 500 ml of water. The resulting yellow solid was collected, slurried in a mixture of 250 ml of acetic acid and 100 ml of water, heated at 100 C for 2 hours cooled and diluted with 500 ml of water. The white crystals were collected, giving 46.0 g of 4-bromo-4'-nitrodiphenylsulfone. A 37.6 g portion of the above nitro derivative was reduced to the corresponding amino derivative. A 3.11 g portion of the above amino derivative tzars slurried in 75 ml of dichloromethane, 2.15 ml of triethylamine was added and the mixture was cooled in an ice bath. A 1.13 ml portion of acetylchloride in 40 ml of dichloromethane was added dropwise over 30 minutes, the ice bath was removed and the mixture was stirred over 48 hours. The solution was worked up as described in Example 13, giving 2.5 g of the desired product as tan crystals, mp 195-199 C. Example 15 N-[4-(3-Chlorophenylsulfonyl)-phenyllacetamide To a cooled solution of 3.0 g of 3-chlorophenyl -4'-aminophenylsulfone in 60 ml of dichloromethane was added simultaneously and dropwise 0.92 ml of acetylchloride and 1.72 ml of triethylamine over a 10 minute period. The reaction was stirred at room temperature for 2 hours, then allowed to stand overnight and poured into 60 ml of water. The organic layer was separated and evaporated to a residue. The residue was crystallized from toluene, giving 3.2 g of the desired product, mp 149-1500C. Example 16 N-[4-[(4-Fluorophenyl)thiolphenyllacetamide 4-Fluoro-4 '-nitrodiphenylsulfide was hydrogenated in dioxane, using Raney nickel catalyst, giving 4-[(4fluorophenyl)thio]-benzenamine. A 2.19 g portion of this amine was dissolved in 50 ml of dichloromethane, cooled in an ice bath and treated with 1.52 g of triethylamine. The mixture was then treated dropwise with a solution of 1.18 g of acetyl chloride in 20 ml of dichloromethane over 20 minutes. This mixture was stirred at room temperature overnight, then the solution was washed successively with water, saturated aqueous sodium bicarbonate, water and brine, dried over magnesium sulfate, filtered and concentrated to dryness. The residue was recrystallized from methanol-water, giving 2.26 g of the desired product as colorless crystals, mp 140-141C. Example 17 N-(4-Fluorophenvl)sulfinvlinhenvliacetamide A solution of 1.3 f of N-[4-[(4-fluorophenyl)- thio]phenyl]acetamide in 75 ml of glacial acetic acid was heated to 50-700C, treated with 0.17 g of 30% hydrogen peroxide and stirred for one hour. The mixture was diluted with 5 volumes of ice water and stirred. The solid was collected, washed with water and dried, giving 1.2 g of the desired product as a colorless solid, mp 169-170 C. Example 18 N-[4-[(4-Methoxyphenyl)thio]phenyl]acetamide 4-Methoxy-4'-nitrodiphenylsulfide was reduced to 4-[(4-methoxyphenyl)thio] benzeneamine as described in Example 16 and then further reacted as described in Example 16, giving the desired product as a pale yellow solid, mp 100-1020C. Example 19 N-[4-[(4-Methoxyphenyl)sulfinylgphenyllacetamide An 8.2 g portion of n-[4-[(4-methoxyphenyl)- thio]phenyl]acetamide was reacted as described in Example 17, giving 6.7 g of the desired product as a pale yellow solid, mp 63-650C. Example 20 N-[4-[(4-Chlorophenyl)thio]phenyl]acetamide 4-Chloro-4'-nitrodiphenylsulfide was reduced to 4-[(4-chlorophenyl)thio]benzeneamine and then further eacted as described in Example 16, giving the desired product as beige crystals, mp 140-141 0C. Example 21 N-[4-[(4-Chlorophenyl)sulfinyl]phenyllacetamide An 8 g portion of N-14-1(4-chlorophenyl)thio]- phenyl]acetamide was reacted as described in Example 17, giving 7 g of the desired product as a colorless solid, mp 160-162 C. Example 22 N-[4-[(4-Bromophenyl)thio]phenyl]acetamide 4-Bromo-4'-nitrodiphenylsulfide was reduced to 4-[(4-bromophenyl)thio]benzeneamine and further reacted as described in Example 16, giving the desired product as beige crystals, mp 153-155 C. Example 23 N-[4-[(4-Bromophenyl)sulfinyl]phenyl]acetamide A 10 g portion of N-[4-[(4-bromophenyl)thio]- phenyl]acetamide was reacted as described in Example 17, giving 2.31 g of the desired product as beige crystals, mp 190-191 C. Example 24 (4 Fluorophenyl)sulfonyl]phenyl]-2-methyl -propanamide A 2.51 g portion of 4-[4-fluorophenyl)sulfonyl] -benzeneamine was reacted as described in Example 16, using propionyl chloride in place of acetyl chloride giving 2.74 g of the desired product, mp 112-1150C. Example 25 N-14-(Pbenylthio)-phenyl]acetamide 4-Nitrodiphenyl sulfide was reduced to 4 -(phenylthio)benzeneamine and further reacted as described in Example 16, giving the desired product as orange crystals, mp 142-144 C. Example 26 N-[4-(Phenylsulfinyl)phenyl]acetamide A 2.43 g portion of N-[4-(phenylthio)phenyl] acetamide was reacted as described in Example 17, giving 1.1 g of the desired compound as a colorless solid, mp 135-137 0C. Example 27 p-(p-Fluorophenylsulfonyl)aniline A mixture comprised of 38.4 g of 4-fluorothiophenol, 47.1 g of p-chloronitrobenzene, 39 g of sodium carbonate, 120 ml of water and 150 ml of ethanol was stirred at 1000C for 19 hours and then poured into 500 ml of water. The solid was collected, washed with water and recrystallized from ethanol, giving 66.4 g of 4-fluoro4'-nitrodiphenyl sulfide. A 30 g portion of the above compound was added to a mixture of 200 ml of glacial acetic acid and 50 ml of 30% hydrogen peroxide and stirred at 100 C for one hour. The mixture was cooled, 15 ml of water was added and the mixture was refrigerated overnight. The crystals were collected giving 32.7 g of 4-fluoro-4'.-nitrodiphenyl sulfone. A mixture of 10.0 g of the above sulfone, 200 ml of dioxane and 3 ml of Raney nickel catalyst in water was hydrogenated in a Parr apparatus until hydrogen uptake was complete. The catalyst was removed by filtration. The filtrate was concentrated in vacuo and the residue crystallized from 200 ml of ethanol, giving 7.8 g of the desired product as colorless crystals, mp 206-2080C. Example 28 p- (o-Nitrophenylthio) aniline To a stirred mixture of 12.51 g of p-aminothio -phenol and 11.6 g of sodium carbonate in 200 ml of ethanol and 50 ml of water was added 15.7 g of 1-chloro-2-nitro -benzene. The mixture was refluxed with stirring for 4 hours, then cooled and filtered. The filtrate was treated with dichloromethane and water and the resulting solid was crystallized from toluene giving 18.57 g of the desired product, mp 78-820C. Example 29 o-(p-Chlorophenylthio)aniline A 13.35 g portion of 2-nitro-4'-chlorodiphenyl sulfide was reduced as described in Example 27, giving the desired product as 11.7 g of an amber oil. Example 30 p-(2,4,5-Trichlorophenylsulfonyl)aniline A mixture of 32.03 g of 2,4,5-tricholorthio -phenol, 19.5 g of sodium carbonate and 23.55 g of 4-chloro -nitrobenzene in water and ethanol was reacted as described in Example 27, giving 30 g of 2,4,5-trichloro-4'-nitrodi -phenyl sulfide. A 20 g portion of the above sulfide was reacted with 30% hydrogen peroxide and glacial acetic acid as described in Example 27, giving 19.0 g of 2,4,5-trichloro -4'-nitrodiphenyl sulfone. A 15.0 g portion of the above sulfone was reduced in dioxane as described in Example 27, giving 11.3 g of the desired product, mp 195-197 C. Example 31 p- (p-Bromophenylsulfonyl) aniline A mixture of 56.7 g of 4-bromothiophenol, 47.1 g 4-chloronitrobenzene and 39 g of sodium carbonate in water and ethanol was reacted as described in Example 27, giving 78.3 g of 4-bromo-4'-nitrodiphenyl sulfone. A 30 g portion of the above sulfone was reduced in dioxane as described in Example 27, giving 20.0 g of the desired product as white crystals, mp 198-2000C. Example 32 o-(Phenylthio)aniline A 20.0 g portion of 2-nitrodiphenyl sulfide was reduced in dioxane as described in Example 27, giving 17.1 g of the desired product as an oil. Example 33 p-(2,4,5-Trichlorophenylthio)aniline A 5 g portion of 2,4,5-trichloro-4'-nitrodiphenyl sulfide in dioxane was reduced as described in Example 27, giving 2.0 g of the desired product as pink crystals, mp 118-1200C. Example 34 p-(2,5-Dichlorophenylthio)aniline A mixture of 25 g of 2,5-dichlorobenzennthiol, 19.5 g of sodium carbonate and 22.05 g of l-chloro-4nitrobenzene in ethanol and water was reacted as described in Example 27, giving 32.5 g of 2.5-dichloro-4'-nitrodiphenyl sulfide. A 10.0 g portion of the above compound was reduced in dioxane as described in Example 27, giving 8.5 g of the desired product as an off-white solid, mp 67 690C. Example 35 p-(m-Chlorophenylsulfonsl)aniline 3-Chloro-4 '-nitrodiphenylsulfone was prepared from 3-chlorothiophenol, g-chloronitrobenzene and sodium carbonate in ethanol-water, followed by reaction with hydrogen peroxide in glacial acetic acid, all as described in Example 27. Example 36 p-(3,4-Dichlorophenylthio)aniline A mixture of 25 g of 3,4-dichlorobenzenethiol, 19.5 g of sodium carbonate, 22.05 g of 1-chloro-4-nitro-benzene, 100 ml of ethanol and 75 ml of water was reacted as described in Example 27, giving 34.8 g of 3,4-dichloro--4'nitrodiphenylsulfide. A 15.0 g portion of the above compound in dioxane was reduced as described in Example 27, giving 13.3 g of the desired product as a yellow solid, mp 52-550C. Example 37 p- (p-Methoxyphenylsulfonyl)aniline A 20 g portion of 4-methoxy-4'-nitrodiphenylsulfide was reacted with hydrogen peroxide and glacial acetic acid as described in Example 27, giving 21.3 g of 4methoxy-4'-nitrodiphenylsulfone. A 17.0 g portion of the above compound in dioxane was reduced as described in Example 27, giving 14.0 g of the desired product s a white solid, mp 149-151OC Example 38 p-(3,4-Dichlorophenylsulfonyl)aniline A 15 g portion of 3,4-dichloro-4'-nitrodiphenylsulfide was reacted with hydrogen peroxide in glacial acetic acid as described in Example 27, giving 15.9 g of 3,4-dichloro -4'-nitrodiphenylsulfone. A 12.0 g portion of the above compound in dioxane was reduced as described in Example 27, giving 1.9 g of crude product, which was recrystallized from ethanol, giving 5.5 g of the desired product as white crystals, mp 214 2160C. Example 39 3-Chloro-4-(p-chlorophenylsulfonyl)aniline A mixture of 25.9 g of 4-chlorothiophenol, 34.4 g of 1,2-dichloro-4-nitrobenzene, 19.5 g of sodium carbonate, 100 ml of ethanol and 75 ml of water was reacted as described in Example 27, giving 30.1 g of 2' ,3-dichloro-4'-nitrodiphenyl sulfide. A 15.0 g portion of the above compound was reacted with hydrogen peroxide and glacial acetic acid as described in Example 27, giving 16.5 g of 2',3-dichloro4'-nitrodiphenlyl sulfone. A 13.0 g portion of the above sulfone in dioxane was reduced as described in Example 27, giving 8.7 g of the desired product as pink crystals, mp 175177 C. Example 40 p-(p-Chlorophenylsulfonyl)aniline This compound is commercially available from Alfred Bader Chemical Company. Example 41 2-[lp-(p-Aminophenylsulfonyl)phenyl]amino]ethanol This compound is commercially available from Alfred Bader Chemical Company. Example 42 4-Acetylamino-4 '-aminodiphenylsulfone This compound is commercially available from Alfred Bader Chemical Company. Example 43 p-[(p-Bromophenyl)thio]benzeneamine A 25.0 g portion of 4-bromo-4'-nitrodiphenylsulfide was dissolved in 150 ml of dioxane. A solution of Raney nickel catalyst in water was added and the mix -ture was hydrogenated for 2 hours, then filtered through diatomaceus earth. The filtrate was concentrated in vacuo to an oil which was dissolved in 100 ml of ether and concentrated in vacuo, giving 21.2 g of the desired product as pale yellow, mp 64-66OC Example 44 p-[(p-Methoxyphenyl)thio]benzeneamine A mixture of 28 g of l-chloro-4-nitrobenzene, 25 g of 4-methoxybenzenthiol, 19.5 g of sodium carbonate2 100 ml of ethanol and 75 ml of water was heated at 100 C. for 4 hours, then poured into 600 ml of cold water. The solid was collected and crystallized from 150 ml of ethanol, giving 39.8 g of 4-methoxy-4'-nitrodiphenylsulfide. A 15 g portion of the above compound in dioxane was reduced as described in Example 43, giving 12.7 g of the desire product as a pale-yellow solid, mp 89-9l0C. Example 45 p-[(p-Fluorophenyl)thiolbenzeneamine A 7 g portion of 4-fluoro-4'-nitrodiphenylsul- fide in 120 ml of p-dioxane was reduced as described in Example 17, giving 5.5 g of the desired product as a pale pink solid, mp 55-570C. Example 46 p-[ (p-Cblorophenyl) thio]benzeneamine A 13.3 g portion of 4-chloro-4'-nitrodiphenylsulfide in 150 mi of dioxane was reduced as described in Example 43, giving 9.62 g of the desired product as light pink crystals, mp 61-620C. Example 47 ±-[ (±Fluorophenyl) thio]-N,N- dimethylbenzeneamine A suspension of 12.5 g of 4-fluoro-4'-nitrodiphenylsulfide, 4.5 g of 37% formaldehyde, 1 g of sodium acetate and 6 g of Raney nickel catalyst in 130 ml of ethanol was hydrogenated in a Parr shaker for 16 hours. The mixture was filtered and the filtrate treated with twice its volume of water giving a precipitate which was collected and recrystallized from 40 ml of methanol, giving the desired product, mp 70-720C. Example 48 ±-[ (±-Fluorophenyl)sulfinyl] - N.N-dimethylbenzeneamine A 2.47 g portion of p-[(p-fluorophenyl)thio]- -N,N-dimethylbenzeneamine was dissolved in 40 ml of glacial acetic acid and clarified by filtration. The filtrate was treated at 400C with 1.4 ml of 30% hydrogen peroxide, with stirring for one hour. Three volumes of water were added and the mixture was stirred overnight. The white solid was collected, giving 1.62 g of the desired product mp 113-1150C. Example 49 g-[(p-Fluorophenyl)sulfinyl]benzeneamide A 2.19 g portion of ±-[(-fluorophenyl)thio]- benzeneamine was dissolved in 50 ml of dichloromethane. This solution was treated with 1.52 g of triethylamine while cooled in an ice bath and then treated dropwise with a solution of 1.18 g of acetyl chloride in 20 ml of dichloromethane over a period of 20 minutes. The mixture was stirred at room temperature overnight, then washed successively with water, saturated aqueous sodium bicarbonate, water and sodium chloride solution, then dried over magnesium sulfate, filtered and concentrated to dryness, giving 2.68 g of p-[(2-fluorophenyl)thio]benzene- acetamide. A 1.3 g portion of the above compound in 25 ml of acetic acid at 50-700C was treated with 0.17 g of 30% hydrogen peroxide and stirred for one hour. The mixture was diluted with 5 volumes of ice water, giving 1.2 g of p-[(p-fluorophenyl)sulfinyl]benzeneacetamide. A solution of 1.38 g of the above sulfonyl derivative in 50 ml of ethanol containing 5 ml of 7N hydrochloric acid in isopropanol was heated at reflux for 1/2 hour and then evaporated to dryness. The residue was taken up in water, giving an oil which was crystallized from methanol and water, giving 0.2 g of the desired product as a colorless solid, mp 145-1470C. Example 50 ±- (Phenylthio)benzeneamine A 15 g portion of 4-nitrodiphenylsulfide was hydrogenated with Raney nickel cataylst in dioxane, giving 7.8 g of the desired product as yellow crystals, mp 94-960C. Example 51 p-[(g-Chlorophenyl)sulfinyl]benzeneamine p-[(p-Chlorophenyl)thio]benzeneamine was converted to D[(E-chlorophenyl)thio]benzeneaacetamide by the procedure described in Example 49 and then to chlorophenyl)sulfinyl]benzeneacetamide and then (still by the procedure of Example 49) converted to the desired product, colorless crystals, mp 161-1620C. Example 52 E-[(E-Methoxyphenyl) sulfinyljbenzeneamine Following the procedure of Example 49, p-[(p -methoxyphenyl)thio]benzeneamine was converted to p-[(p- -methoxyphenyl)thio]benzeneacetamide, which was converted to p-[(p-methoxyphenyl)sulfinyl]benzeneacetamide and finally to the desired product, a colorless solid, mp 135 -1400C.

Claims: We claim: 1. A method of modulating the immune response system in a warm-blooded animal which comprises administering to said animal an effective amount of a compound selected from the group consisting of those of the formula: EMI35.1 wherein R1 is hydrogen, nitro or chloro; R2 is hydrogen or chloro; R3 is hydrogen, fuoro, chloro, bromo, nitro, alkoxy (C1-C3), acetylamino, B-hydroxyethylamino or -NHCOCH2NHCH3; R4 is hydrogen of chloro; Rs is hydrogen or chloro; R6 is hydrogen or alkyl (C1-C3); R7 is hydrogen, alkyl (C1-C3), -COCH2NH2, -COCH2NHCH3, -COCH2CH2C1, -COCH2C1, -CH2CN, (5-lH-tetrazolyl) methyl or alkanoyl (C2-C5); and Z is thio, sulfinyl or sulfonyl with the proviso that only one of R1, R2, R3 and R4 may be other than hydrogen except when R1, R2, R3 and R4 are all hydrogen or chloro; and the pharmacoligically acceptable acid-addition salts thereof; in association with a pharmaceutically acceptable carrier. -2. The method according to Claim 1 wherein the compound is 3-chloro-4'-(g-nitrophenylthio)propionanilide. 3. The method according to Claim 1 wherein the compound is 4'-(p-chlorophenylsulfonyl)acetanilide. 4. The method according to Claim 1 wherein the compound is N-[4-(4-fluorophenylsulfonyl)phenyl]-acetamide. 5. The method according to Claim 1 wherein the compound is g-(2,5-dichlorophenylthio)aniline. 6. A compound selected from the group consisting of those of the formula: EMI35.2 wherein R8 is hydrogen, fluoro, chloro or bromo and Rg is hydrogen or chloro with the proviso that one of R8 and Rg must be hydrogen but R8 and R9 may not both be hydrogen and R10 is -CH2CN, -COCH2NH2 or (5-lH-tetrazolyl)methyl; and the pharmacologically acceptable acid-addition salts thereof. 7. The compound according to Claim 5 wherein R8 is chloro, R9 is hydrogen, and R10 is -CH2CN; [p-(pchlorophenylsulfonyl)anilino]acetonitrile. 8. The compound according to Claim 5 wherein R8 is hydrogen, Rg is chloro, and R10 is -COCH2NH2; 2amino-4'-(m-chlorophenylsulfonyl)acetanilide. 9. The compound according to Claim 5 wherein R8 is fluoro, Rg is hydrogen, and R10 is -COCH2NH2; 4-fluoro-4'-(2-aminoacetamido)diphenylsulfone. 10. The compound according to Claim 5 wherein R8 is chloro, Rg is hydrogen, and R10 is (5-lH-tetrazolyl)- methyl; 5-[p-(p-chlorophenylsulfonyl)anilinomethyl]-1Htetrazole.

Inventors: FIELDS, THOMAS LYNN, KANG, SOON MOK, LANG, STANLEY ALBERT, JR., LIN, YANK-I, WILKINSON, RAYMOND GEORGE
Applicants: AMERICAN CYANAMID COMPANY
Application year: 1983
Main classification: A61K31
IPC codes: A61K31, C07D257, C07C317